Literature DB >> 20973775

Roles of affinity and lipophilicity in the slow kinetics of prostanoid receptor antagonists on isolated smooth muscle preparations.

R L Jones1, D F Woodward, J W Wang, R L Clark.   

Abstract

BACKGROUND AND
PURPOSE: The highly lipophilic acyl-sulphonamides L-798106 and L-826266 showed surprisingly slow antagonism of the prostanoid EP₃ receptor system in guinea-pig aorta. Roles of affinity and lipophilicity in the onset kinetics of these and other prostanoid ligands were investigated. EXPERIMENTAL APPROACH: Antagonist selectivity was assessed using a panel of human recombinant prostanoid receptor-fluorimetric imaging plate reader assays. Potencies/affinities and onset half-times of agonists and antagonists were obtained on guinea-pig-isolated aorta and vas deferens. n-Octanol-water partition coefficients were predicted. KEY
RESULTS: L-798106, L-826266 and the less lipophilic congener (DG)-3ap appear to behave as selective, competitive-reversible EP₃ antagonists. For ligands of low to moderate lipophilicity, potency increments for EP₃ and TP (thromboxane-like) agonism on guinea-pig aorta (above pEC₅₀ of 8.0) were associated with progressively longer onset half-times; similar trends were found for TP and histamine H₁ antagonism above a pA₂ limit of 8.0. In contrast, L-798106 (EP₃), L-826266 (EP₃, TP) and the lipophilic H₁ antagonists astemizole and terfenadine exhibited very slow onset rates despite their moderate affinities; (DG)-3ap (EP₃) had a faster onset. Agonism and antagonism on the vas deferens EP₃ system were overall much faster, although trends were similar. CONCLUSIONS AND IMPLICATIONS: High affinity and high liphophilicity may contribute to the slow onsets of prostanoid ligands in some isolated smooth muscle preparations. Both relationships are explicable by tissue disposition under the limited diffusion model. EP₃ antagonists used as research tools should have moderate lipophilicity. The influence of lipophilicity on the potential clinical use of EP₃ antagonists is discussed.
© 2011 The Authors. British Journal of Pharmacology © 2011 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20973775      PMCID: PMC3042197          DOI: 10.1111/j.1476-5381.2010.01087.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  56 in total

Review 1.  Mechanisms underlying variability in response to drug therapy: implications for amiodarone use.

Authors:  D M Roden
Journal:  Am J Cardiol       Date:  1999-11-04       Impact factor: 2.778

Review 2.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings.

Authors:  C A Lipinski; F Lombardo; B W Dominy; P J Feeney
Journal:  Adv Drug Deliv Rev       Date:  2001-03-01       Impact factor: 15.470

3.  Pharmacological characterization of prostanoid receptors mediating vasoconstriction in human umbilical vein.

Authors:  Federico Manuel Daray; Ana Itatí Minvielle; Soledad Puppo; Rodolfo Pedro Rothlin
Journal:  Br J Pharmacol       Date:  2003-08       Impact factor: 8.739

4.  The role of prostaglandin E receptor subtypes (EP1, EP2, EP3, and EP4) in bone resorption: an analysis using specific agonists for the respective EPs.

Authors:  T Suzawa; C Miyaura; M Inada; T Maruyama; Y Sugimoto; F Ushikubi; A Ichikawa; S Narumiya; T Suda
Journal:  Endocrinology       Date:  2000-04       Impact factor: 4.736

5.  In vitro pharmacological characterization of the prostanoid receptor population in the non-pregnant porcine myometrium.

Authors:  Jinshan Cao; Mikeremu Shayibuzhati; Tsuyoshi Tajima; Takio Kitazawa; Tetsuro Taneike
Journal:  Eur J Pharmacol       Date:  2002-05-03       Impact factor: 4.432

6.  Characterization of prostanoid receptors mediating contraction of the gastric fundus and ileum: studies using mice deficient in prostanoid receptors.

Authors:  Y Okada; A Hara; H Ma; C Y Xiao; O Takahata; Y Kohgo; S Narumiya; F Ushikubi
Journal:  Br J Pharmacol       Date:  2000-10       Impact factor: 8.739

7.  Pharmacological characterization of a novel antiglaucoma agent, Bimatoprost (AGN 192024).

Authors:  D F Woodward; A H-P Krauss; J Chen; Y Liang; C Li; C E Protzman; A Bogardus; R Chen; K M Kedzie; H A Krauss; D W Gil; A Kharlamb; L A Wheeler; D Babusis; D Welty; D D-S Tang-Liu; M Cherukury; S W Andrews; R M Burk; M E Garst
Journal:  J Pharmacol Exp Ther       Date:  2003-01-24       Impact factor: 4.030

8.  QSAR and the rational design of long-acting dual D2-receptor/beta 2-adrenoceptor agonists.

Authors:  Rupert P Austin; Patrick Barton; Roger V Bonnert; Roger C Brown; Peter A Cage; David R Cheshire; Andrew M Davis; Iain G Dougall; Francis Ince; Garry Pairaudeau; Alan Young
Journal:  J Med Chem       Date:  2003-07-17       Impact factor: 7.446

9.  Histamine H1 receptor antagonism by cetirizine in isolated guinea pig tissues: influence of receptor reserve and dissociation kinetics.

Authors:  Bernard Christophe; Brigitte Carlier; Michel Gillard; Pierre Chatelain; Mike Peck; Roy Massingham
Journal:  Eur J Pharmacol       Date:  2003-05-30       Impact factor: 4.432

10.  Structure-activity relationship of biaryl acylsulfonamide analogues on the human EP(3) prostanoid receptor.

Authors:  M Gallant; M C Carrière; A Chateauneuf; D Denis; Y Gareau; C Godbout; G Greig; H Juteau; N Lachance; P Lacombe; S Lamontagne; K M Metters; C Rochette; R Ruel; D Slipetz; N Sawyer; N Tremblay; M Labelle
Journal:  Bioorg Med Chem Lett       Date:  2002-09-16       Impact factor: 2.823

View more
  5 in total

1.  EP3 receptor deficiency attenuates pulmonary hypertension through suppression of Rho/TGF-β1 signaling.

Authors:  Ankang Lu; Caojian Zuo; Yuhu He; Guilin Chen; Lingjuan Piao; Jian Zhang; Bing Xiao; Yujun Shen; Juan Tang; Deping Kong; Sara Alberti; Di Chen; Shenkai Zuo; Qianqian Zhang; Shuai Yan; Xiaochun Fei; Fei Yuan; Bin Zhou; Shengzhong Duan; Yu Yu; Michael Lazarus; Yunchao Su; Richard M Breyer; Colin D Funk; Ying Yu
Journal:  J Clin Invest       Date:  2015-02-09       Impact factor: 14.808

2.  PGE2 maintains the tone of the guinea pig trachea through a balance between activation of contractile EP1 receptors and relaxant EP2 receptors.

Authors:  J Säfholm; S-E Dahlén; I Delin; K Maxey; K Stark; L-O Cardell; M Adner
Journal:  Br J Pharmacol       Date:  2013-02       Impact factor: 8.739

3.  The effect of the EP3 antagonist DG-041 on male mice with diet-induced obesity.

Authors:  Ryan P Ceddia; Jason D Downey; Ryan D Morrison; Maria P Kraemer; Sarah E Davis; Jing Wu; Craig W Lindsley; Huiyong Yin; J Scott Daniels; Richard M Breyer
Journal:  Prostaglandins Other Lipid Mediat       Date:  2019-07-02       Impact factor: 3.072

4.  Interaction of prostanoid EP₃ and TP receptors in guinea-pig isolated aorta: contractile self-synergism of 11-deoxy-16,16-dimethyl PGE₂.

Authors:  R L Jones; D F Woodward
Journal:  Br J Pharmacol       Date:  2011-01       Impact factor: 8.739

5.  Acute effects of prostaglandin E1 and E2 on vascular reactivity and blood flow in situ in the chick chorioallantoic membrane.

Authors:  D R Harland; L D Lorenz; K Fay; B E Dunn; S K Gruenloh; J Narayanan; E R Jacobs; M Medhora
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2012-08-02       Impact factor: 4.006

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.